KisoJi

Developer of multi-specific antibodies for cancer treatment. It offers tri-specific immuno-oncology antibody candidates which include KJ-101 for neuroendocrine solid tumors, KJ-102 for acute myeloid leukemia, and KJ-103 for TROP-2 Expressing solid tumors.